Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s share price was up 3.1% during mid-day trading on Friday . The company traded as high as $4.95 and last traded at $4.93, with a volume of 1,655,708 shares traded. The stock had previously closed at $4.78.

A number of equities analysts have issued reports on SGYP shares. Rodman & Renshaw reissued a “buy” rating and issued a $15.00 target price on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. BTIG Research reaffirmed a “buy” rating and set a $11.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Monday, May 16th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Synergy Pharmaceuticals in a report on Monday, May 9th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.37.

The company’s 50-day moving average price is $4.02 and its 200-day moving average price is $3.54. The company’s market cap is $895.44 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.03. Equities research analysts expect that Synergy Pharmaceuticals Inc. will post ($1.03) EPS for the current fiscal year.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.